{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:59:02Z","timestamp":1779242342215,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T00:00:00Z","timestamp":1448841600000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bbmt.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T11:32:49Z","timestamp":1442057569000},"page":"1883-1887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hematopoietic Cell Transplantation as Curative Therapy for\u00a0Patients with Myelofibrosis: Long-Term Success in all Age\u00a0Groups"],"prefix":"10.1016","volume":"21","author":[{"given":"H. Joachim","family":"Deeg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Farnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effie","family":"W. Petersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.09.005_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-015-1983-5","article-title":"Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011","author":"Deadmond","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.005_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib3","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.005_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.005_bib6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib8","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib9","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors (Review)","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib11","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib14","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3324\/haematol.12828","article-title":"Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"93","author":"Patriarca","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.005_bib15","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a\u00a0prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib16","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.005_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08582.x","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age","volume":"153","author":"Samuelson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.09.005_bib20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3324\/haematol.2011.061168","article-title":"DIPSS scores, pre-transplant therapy and chronic GVHD determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Ditschkowski","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.005_bib21","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib22","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3324\/haematol.2013.094284","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.09.005_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib26","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2796.2011.02457.x","article-title":"HIV reservoirs and the possibility of a cure for HIV infection (Review)","volume":"270","author":"Palmer","year":"2011","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.bbmt.2015.09.005_bib29","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood-2010-07-259358","article-title":"Who is fit for allogeneic transplantation?","volume":"116","author":"Deeg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib30","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less then 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.09.005_bib31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.005_bib32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.005_bib33","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.09.005_bib34","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.09.005_bib35","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.09.005_bib36","first-page":"481","article-title":"Allelic frequency of a p53 polymorphism in human lung cancer","volume":"1","author":"Weston","year":"1992","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.bbmt.2015.09.005_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.09.005_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115006102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115006102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:52:58Z","timestamp":1761058378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115006102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1083879115006102"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Cell Transplantation as Curative Therapy for\u00a0Patients with Myelofibrosis: Long-Term Success in all Age\u00a0Groups","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}